KR20230005284A - 소아 특발성 관절염을 치료하기 위한 재료 및 방법 - Google Patents

소아 특발성 관절염을 치료하기 위한 재료 및 방법 Download PDF

Info

Publication number
KR20230005284A
KR20230005284A KR1020227041143A KR20227041143A KR20230005284A KR 20230005284 A KR20230005284 A KR 20230005284A KR 1020227041143 A KR1020227041143 A KR 1020227041143A KR 20227041143 A KR20227041143 A KR 20227041143A KR 20230005284 A KR20230005284 A KR 20230005284A
Authority
KR
South Korea
Prior art keywords
tnf
jia
antibody
antibodies
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227041143A
Other languages
English (en)
Korean (ko)
Inventor
카렌 벤슬리
마이클 클라크
조슬린 류
젠휴아 슈
Original Assignee
얀센 바이오테크 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 바이오테크 인코포레이티드 filed Critical 얀센 바이오테크 인코포레이티드
Priority claimed from PCT/IB2021/053429 external-priority patent/WO2021220140A1/en
Publication of KR20230005284A publication Critical patent/KR20230005284A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Farming Of Fish And Shellfish (AREA)
KR1020227041143A 2020-04-27 2021-04-26 소아 특발성 관절염을 치료하기 위한 재료 및 방법 Pending KR20230005284A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063015902P 2020-04-27 2020-04-27
US202063015889P 2020-04-27 2020-04-27
US202063015894P 2020-04-27 2020-04-27
US63/015,902 2020-04-27
US63/015,894 2020-04-27
US63/015,889 2020-04-27
PCT/IB2021/053429 WO2021220140A1 (en) 2020-04-27 2021-04-26 Materials and methods for treating juvenile idiopathic arthritis

Publications (1)

Publication Number Publication Date
KR20230005284A true KR20230005284A (ko) 2023-01-09

Family

ID=78336251

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227041143A Pending KR20230005284A (ko) 2020-04-27 2021-04-26 소아 특발성 관절염을 치료하기 위한 재료 및 방법

Country Status (9)

Country Link
EP (1) EP4143226A4 (https=)
JP (1) JP2023524668A (https=)
KR (1) KR20230005284A (https=)
CN (1) CN115461365A (https=)
AU (1) AU2021263136A1 (https=)
BR (1) BR112022021766A2 (https=)
CA (1) CA3127807A1 (https=)
IL (1) IL297623A (https=)
MX (1) MX2022013502A (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102961746B (zh) * 2005-05-16 2016-06-15 艾伯维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
US10465003B2 (en) * 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
KR20190113858A (ko) * 2017-01-30 2019-10-08 얀센 바이오테크 인코포레이티드 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법

Also Published As

Publication number Publication date
EP4143226A1 (en) 2023-03-08
EP4143226A4 (en) 2024-05-29
CN115461365A (zh) 2022-12-09
MX2022013502A (es) 2023-02-01
CA3127807A1 (en) 2021-10-27
AU2021263136A1 (en) 2023-01-05
IL297623A (en) 2022-12-01
JP2023524668A (ja) 2023-06-13
BR112022021766A2 (pt) 2022-12-13

Similar Documents

Publication Publication Date Title
JP2022137167A (ja) 活動性乾癬性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
KR20190115042A (ko) 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
JP2025157225A (ja) 乾癬性関節炎を治療するための抗ｔｎｆ抗体組成物及び方法
KR20220030952A (ko) 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
US20210340245A1 (en) Materials and Methods for Treating Juvenile Idiopathic Arthritis
JP7689074B2 (ja) 若年性特発性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
KR20230005284A (ko) 소아 특발성 관절염을 치료하기 위한 재료 및 방법
JP2025084901A (ja) 乾癬性関節炎の治療方法で使用するための抗ｔｎｆ抗体組成物
KR20230121110A (ko) 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물,및 방법
CN116670167A (zh) 用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法
EA051501B1 (ru) Композиции антител к фно для применения в способах лечения псориатического артрита
EA047762B1 (ru) Композиции антитела к фно и способы лечения ювенильного идиопатического артрита

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902